CU24064B1 - Derivados de 1h-imidazo-[4,5-c]-quinolinona - Google Patents
Derivados de 1h-imidazo-[4,5-c]-quinolinonaInfo
- Publication number
- CU24064B1 CU24064B1 CU2011000221A CU20110221A CU24064B1 CU 24064 B1 CU24064 B1 CU 24064B1 CU 2011000221 A CU2011000221 A CU 2011000221A CU 20110221 A CU20110221 A CU 20110221A CU 24064 B1 CU24064 B1 CU 24064B1
- Authority
- CU
- Cuba
- Prior art keywords
- imidazo
- derivatives
- treatment
- diseases
- quinolinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere al uso de derivados de 1H-imidazo-[4,5-c]-quinolinona y de las sales de los mismos en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido y para la elaboración de las preparaciones farmacéuticas para el tratamiento de estas enfermedades: a los derivados de 1H-imidazo-[4,5-c]-quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido: a un método para el tratamiento contra estas enfermedades, el cual comprende administrar los derivados de 1H-imidazo-[4,5-c]-quinolinona a un animal de sangre caliente, en especial a un ser humano: a las preparaciones farmacéuticas que comprenden un derivado de 1H-imidazo-[4,5-c]-quinolinona, en especial para el tratamiento de una enfermedad dependiente de la cinasa de proteína y/o de lípido: a los derivados 1H-imidazo-[4,5-c]-quinolinona novedosos: y a un proceso para la preparación de los derivados de 1H-imidazo-[4,5-c]-quinolinona novedosos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18414109P | 2009-06-04 | 2009-06-04 | |
PCT/EP2010/057719 WO2010139731A1 (en) | 2009-06-04 | 2010-06-02 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20110221A7 CU20110221A7 (es) | 2012-03-15 |
CU24064B1 true CU24064B1 (es) | 2014-12-26 |
Family
ID=42697442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2011000221A CU24064B1 (es) | 2009-06-04 | 2011-11-30 | Derivados de 1h-imidazo-[4,5-c]-quinolinona |
Country Status (30)
Country | Link |
---|---|
US (2) | US8476294B2 (es) |
EP (1) | EP2438064A1 (es) |
JP (1) | JP5596137B2 (es) |
KR (1) | KR101445458B1 (es) |
CN (1) | CN102574845B (es) |
AR (1) | AR076949A1 (es) |
AU (1) | AU2010255727B2 (es) |
BR (1) | BRPI1010621A2 (es) |
CA (1) | CA2763821A1 (es) |
CL (1) | CL2011003052A1 (es) |
CO (1) | CO6470887A2 (es) |
CR (1) | CR20110608A (es) |
CU (1) | CU24064B1 (es) |
DO (1) | DOP2011000373A (es) |
EA (1) | EA020715B1 (es) |
EC (1) | ECSP11011500A (es) |
GE (1) | GEP20156267B (es) |
IL (1) | IL216452A0 (es) |
MA (1) | MA33332B1 (es) |
MX (1) | MX2011012943A (es) |
NI (1) | NI201100209A (es) |
NZ (1) | NZ596487A (es) |
PE (1) | PE20120224A1 (es) |
SG (1) | SG176572A1 (es) |
TN (1) | TN2011000626A1 (es) |
TW (1) | TWI464168B (es) |
UA (1) | UA106074C2 (es) |
UY (1) | UY32682A (es) |
WO (1) | WO2010139731A1 (es) |
ZA (1) | ZA201108439B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
CA2819955A1 (en) * | 2010-12-06 | 2012-06-14 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives |
JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
EP2781520B1 (en) * | 2011-11-17 | 2016-05-04 | Xuanzhu Pharma Co., Ltd. | Three-ring pi3k and/or mtor inhibitor |
WO2014141118A1 (en) * | 2013-03-14 | 2014-09-18 | Piramal Enterprises Limited | Imidazo[4,5-c]quinoline derivatives and uses thereof |
MX2015014407A (es) | 2013-04-15 | 2015-12-07 | Du Pont | Amidas fungicidas. |
JP6576929B2 (ja) * | 2013-09-11 | 2019-09-18 | メルク パテント ゲーエムベーハー | ヘテロ環化合物 |
WO2015043398A1 (zh) | 2013-09-30 | 2015-04-02 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
US10989719B2 (en) * | 2013-10-11 | 2021-04-27 | National University Corporation Tokyo Medical And Dental University | Methods for treating spinocerebellar ataxia type I using RPA1 |
CN104447740B (zh) * | 2013-11-20 | 2017-02-22 | 北京富龙康泰生物技术有限公司 | 咪唑酮类衍生物、其药物组合物和用途 |
NO2714752T3 (es) | 2014-05-08 | 2018-04-21 | ||
TWI675827B (zh) | 2014-06-03 | 2019-11-01 | 瑞士商愛杜西亞製藥有限公司 | 吡唑化合物 |
WO2016155884A1 (de) * | 2015-04-02 | 2016-10-06 | Merck Patent Gmbh | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
BR112019007594A2 (pt) | 2016-10-13 | 2019-07-02 | Loyola University Of Chicago | método para bloquear a transmissão do parasita da malária |
BR112019011208A2 (pt) | 2016-12-16 | 2019-10-15 | Idorsia Pharmaceuticals Ltd | combinação farmacêutica, composição farmacêutica, e, kit de partes. |
JP6972144B2 (ja) | 2017-02-06 | 2021-11-24 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | 1−アリール−1−トリフルオロメチルシクロプロパンを合成するための新規な方法 |
JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
BR112020012635A2 (pt) | 2017-12-22 | 2020-12-01 | Ravenna Pharmaceuticals, Inc. | derivados de aminopiridina como inibidores de fosfatidilinositol fosfato quinase |
EP4142710B1 (en) | 2020-09-21 | 2024-01-31 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
ATE400573T1 (de) | 2003-11-21 | 2008-07-15 | Novartis Pharma Gmbh | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
CN101056877B (zh) | 2004-09-14 | 2010-06-09 | 诺华疫苗和诊断公司 | 咪唑并喹啉化合物 |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR20080083270A (ko) | 2005-11-04 | 2008-09-17 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법 |
AU2007323820B2 (en) | 2006-11-20 | 2012-02-23 | Novartis Ag | Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl] -propionitrile |
EP2129379B1 (en) * | 2007-02-20 | 2019-04-10 | Novartis AG | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
PL2182948T3 (pl) * | 2007-07-24 | 2013-07-31 | Novartis Ag | Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR |
US20090082387A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched nvp-bez234 |
CA2717948C (en) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
US20110212053A1 (en) | 2008-06-19 | 2011-09-01 | Dapeng Qian | Phosphatidylinositol 3 kinase inhibitors |
EP2356120B1 (en) * | 2008-09-30 | 2016-10-12 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
-
2010
- 2010-06-02 CN CN201080034616.0A patent/CN102574845B/zh not_active Expired - Fee Related
- 2010-06-02 AR ARP100101942A patent/AR076949A1/es unknown
- 2010-06-02 UA UAA201114398A patent/UA106074C2/uk unknown
- 2010-06-02 SG SG2011085487A patent/SG176572A1/en unknown
- 2010-06-02 PE PE2011002047A patent/PE20120224A1/es not_active Application Discontinuation
- 2010-06-02 EP EP10721029A patent/EP2438064A1/en not_active Withdrawn
- 2010-06-02 GE GEAP201012484A patent/GEP20156267B/en unknown
- 2010-06-02 CA CA2763821A patent/CA2763821A1/en not_active Abandoned
- 2010-06-02 JP JP2012513613A patent/JP5596137B2/ja not_active Expired - Fee Related
- 2010-06-02 NZ NZ596487A patent/NZ596487A/xx not_active IP Right Cessation
- 2010-06-02 BR BRPI1010621A patent/BRPI1010621A2/pt not_active IP Right Cessation
- 2010-06-02 AU AU2010255727A patent/AU2010255727B2/en not_active Ceased
- 2010-06-02 MX MX2011012943A patent/MX2011012943A/es active IP Right Grant
- 2010-06-02 KR KR1020127000098A patent/KR101445458B1/ko not_active IP Right Cessation
- 2010-06-02 MA MA34404A patent/MA33332B1/fr unknown
- 2010-06-02 WO PCT/EP2010/057719 patent/WO2010139731A1/en active Application Filing
- 2010-06-02 US US12/792,471 patent/US8476294B2/en not_active Expired - Fee Related
- 2010-06-02 EA EA201101704A patent/EA020715B1/ru not_active IP Right Cessation
- 2010-06-03 TW TW099117977A patent/TWI464168B/zh not_active IP Right Cessation
- 2010-06-03 UY UY0001032682A patent/UY32682A/es not_active Application Discontinuation
-
2011
- 2011-11-17 ZA ZA2011/08439A patent/ZA201108439B/en unknown
- 2011-11-17 IL IL216452A patent/IL216452A0/en not_active IP Right Cessation
- 2011-11-21 CR CR20110608A patent/CR20110608A/es unknown
- 2011-11-30 CU CU2011000221A patent/CU24064B1/es not_active IP Right Cessation
- 2011-11-30 NI NI201100209A patent/NI201100209A/es unknown
- 2011-12-02 EC EC2011011500A patent/ECSP11011500A/es unknown
- 2011-12-02 DO DO2011000373A patent/DOP2011000373A/es unknown
- 2011-12-02 CL CL2011003052A patent/CL2011003052A1/es unknown
- 2011-12-05 TN TNP2011000626A patent/TN2011000626A1/en unknown
- 2011-12-12 CO CO11170918A patent/CO6470887A2/es active IP Right Grant
-
2013
- 2013-05-24 US US13/901,849 patent/US20140005163A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24064B1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
BRPI0416796A (pt) | compostos orgánicos | |
CR9994A (es) | Vacuna terapéutica | |
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
DOP2011000264A (es) | Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
DOP2005000051A (es) | Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
CU20100062A7 (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b | |
SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
CO6382134A2 (es) | Sales y formas de cristal del 2-metil-2-[4-(metil-2-oxo-8-quinolin-3-3il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]propionitrilo | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
AR104068A1 (es) | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer | |
CY1114251T1 (el) | Χρηση ενος συνδυασμου ο οποιος περιλαμβανει l-kapnitinh ή αλκανοϋλ l-kapnitinh, λιποδιαλυτη βενζοκινονη και ωμεγα-3-πολυακορεστο λιπαρο οξυ για την παρασκευη ενος διαιτητικου συμπληρωματος ή φαρμακου για τη θεραπευτικη αγωγη παθησεων του κερατοειδους | |
UY29846A1 (es) | N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos | |
UY28209A1 (es) | Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos. | |
ECSP12011951A (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria | |
UY29848A1 (es) | (1,3,4)-tiadiazol-2-il-amidas bicíclicas del ácido aril-sulfónico, procesos para su preparación y su uso como productos farmacéuticos | |
CY1110021T1 (el) | ΔΙΑΡΩΜΑΤΙΚΕΣ ΕΝΩΣΕΙΣ ΟΙ ΟΠΟΙΕΣ ΕΝΕΡΓΟΠΟΙΟΥΝ ΥΠΟΔΟΧΕΙΣ ΤΟΥ ΤΥΠΟΥ PPARγ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΑΥΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΚΟΣΜΗΤΙΚΗ Ή ΣΕ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ | |
ECSP055984A (es) | Derivados cicloalquilo que tienen grupos ácido carboxílico bioisostéricos, procesos para su preparación y su uso como composiciones farmacéuticas | |
CU20090226A7 (es) | Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent | ||
FD | Lapse (for not paying fees) |